ASSESSMENT OF ADHERENCE WITH IMMUNOSUPPRESSANT MEDICATIONS IN TRANSPLANT PATIENTS AND THE POTENTIAL COST SAVINGS ASSOCIATED WITH INCREASED ADHERENCE

Author(s)

Spencer E. Harpe, PharmD, PhD, MPH, Assistant Professor1, Gary R Matzke, PharmD, Associate Dean for Clinical Research and Public Policy1, Clifton Osbon, RPh, Staff Pharmacist2, Deepak Ranade, RPh, MBA, President3, Todd Barrett, RPh, President and Chief Executive Officer2, Tim Kaplan, RPh, President and Chief Executive Officer4, Boris Mantell, RPh, Chief Executive Officer5, Henry Skelton, RPh, President and Chief Executive Officer61Virginia Commonwealth University, Richmond, VA, USA; 2 Transcript Pharmacy, Inc, Jackson, MS, USA; 3 Skyemed Pharmacy, Pompano Beach, FL, USA; 4 Amber Pharmacy, Omaha, NE, USA; 5 Echo Drugs, Flushing, NY, USA; 6 F&M Specialty Pharmacy, Jackson, MS, USA

OBJECTIVES: To estimate adherence with immunosuppressant medications in transplant patients served by a group of five specialty pharmacies and to assess the medical cost avoidance associated with improved adherence, where possible. METHODS: Prescription fill data were obtained from five specialty pharmacies for Medicare patients who had prescriptions filled from January 2005 to June 2005 for one of the following medications: azathioprine, mycophenolate mofetil, mycophenolic acid, and sirolimus. Patients were eligible for analysis if they had a prescription filled in both January and June. Medication possession ratios (MPRs) were calculated for each medication over the study period. Patients with MPRs > 0.8 were classified as adherent. Literature-based adherence estimates were obtained for comparison. The 2005 US Renal Data System Annual Data Report was used to gather clinical and economic outcome data for a decision analysis to determine whether differences in adherence resulted in potential cost avoidance associated with a rejected renal graft. RESULTS: In the 1,599 eligible patients, the estimated adherence rate was 84.2%, which was significantly higher than the literature-based estimate of 65% (p<0.01). After applying the adherence estimates to current Medicare cost estimates for functioning renal grafts and failed renal grafts, the estimated yearly cost in study pharmacy patients was $27,853 versus $32,003 using literature-based adherence estimates—a potential cost savings of $4,150 per patient per year. CONCLUSION: These findings suggest that the reduced risk of rejection associated with increased adherence with immunosuppressant agents translates into avoidance of significant costs associated with failed renal grafts. Compared to traditional mail-order or retail pharmacies, the service model used by the study pharmacies involves high levels of patient contact to promote adherence. Policies to ensure appropriate reimbursement, such as CMS's proposed pay-for-performance framework, would be an important step to support and promote optimal patient care.

Conference/Value in Health Info

2007-05, ISPOR 2007, Arlington, VA, USA

Value in Health, Vol. 10, No.3 (May/June 2007)

Code

PUK16

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Urinary/Kidney Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×